Plus Therapeutics 2025 Q2 Earnings Remarkable Turnaround in Net Income

Plus Therapeutics (PSTV) reported its fiscal 2025 Q2 earnings on August 14, 2025, showcasing a significant financial turnaround. The company transitioned from a loss to profitability with a net income of $5.15 million, representing a 275.2% increase from the $2.94 million net loss in the same quarter of 2024.

Revenue
Total revenue for Plus Therapeutics rose 8.7% year-over-year to $1.39 million in 2025 Q2, compared to $1.28 million in 2024 Q2. This increase was driven entirely by grant revenue, which accounted for the full $1.39 million in total revenue.

Earnings/Net Income
The company achieved profitability with an EPS of $0.02 in 2025 Q2, a dramatic improvement from a $0.45 per share loss in the previous year, reflecting a 104.4% positive change. The net income turnaround of $5.15 million, following 17 consecutive years of losses in the same quarter, marked a pivotal moment in the company’s financial history. The company demonstrated a clear ability to reverse long-standing financial challenges.

Price Action
Following the earnings report, the stock price of Plus Therapeutics experienced mixed performance. On the latest trading day, the stock fell 11.11%, and it declined further by 28.55% during the most recent full trading week. However, the month-to-date performance saw a 71.04% surge, indicating potential volatility in the stock.

Post-Earnings Price Action Review
The strategy of buying PSTV shares after a revenue increase quarter-over-quarter on the earnings report date and holding for 30 days has historically underperformed. Over the past three years, this strategy returned -97.72%, significantly lagging the benchmark by 144.20%. The approach demonstrated a high level of risk, with a Sharpe ratio of -0.39 and a maximum drawdown of 0%. These figures underscore the need for caution when using historical revenue performance as a sole investment signal for PSTV.

CEO Commentary
Marc H. Hedrick, M.D., President and Chief Executive Officer, emphasized the company’s steady execution of key strategic initiatives. He highlighted progress in the clinical development of REYOBIQ, including favorable safety and efficacy signals from ongoing trials and active enrollment in a dose optimization study. Additionally, the successful launch of the CNSide diagnostic platform in Texas and plans for nationwide expansion over the next 12 months were noted. The leadership remains optimistic about the commercialization trajectory and clinical progress, aligning with the company’s mission in CNS cancer innovation.

Guidance
The company did not provide explicit forward-looking guidance on financial performance or revenue expectations. However, it outlined strategic plans to expand CNSide testing services beyond Texas into additional states by late 2025 and 2026. The company also intends to advance REYOBIQ clinical trials, including dose optimization and pediatric indications, supported by grant funding. Additionally, it expects to present further clinical data at the SNO/ASCO CNS Metastases Conference in August 2025.

Additional News
Recent non-earnings related news includes the appointment of a Chinese national, Mr. Li Zhensheng, as Economic Adviser by Bauchi State Governor Bala Mohammed, marking a strategic international collaboration. Sokoto State Government disclosed spending N4.7 billion over two years on examination registration for students in external exams like WASSCE, NECO, and UTME. Additionally, the Federal Government of Nigeria announced the launch of a 0% interest loan scheme for tertiary institution workers as part of a broader welfare initiative. These developments reflect broader economic and strategic moves across Nigeria’s political and educational landscape.